CN108403692A - Application of the hydrochloric acid Atipamezole as non-specificity P450 enzyme inhibitors - Google Patents
Application of the hydrochloric acid Atipamezole as non-specificity P450 enzyme inhibitors Download PDFInfo
- Publication number
- CN108403692A CN108403692A CN201810253970.0A CN201810253970A CN108403692A CN 108403692 A CN108403692 A CN 108403692A CN 201810253970 A CN201810253970 A CN 201810253970A CN 108403692 A CN108403692 A CN 108403692A
- Authority
- CN
- China
- Prior art keywords
- hydrochloric acid
- atipamezole
- acid atipamezole
- medical compounds
- enzymes
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
Abstract
The present invention relates to the new opplication of hydrochloric acid Atipamezole, specially application of the hydrochloric acid Atipamezole as non-specificity P450 enzyme inhibitors.Hydrochloric acid Atipamezole does not have significant difference to the rejection ability of each isodynamic enzyme, is especially significantly stronger than 1 ABT to the inhibiting effect of CYP2C9, and species variation is small.The present invention is using veterinary drug hydrochloric acid Atipamezole as a new generation's P450 enzyme nonspecific inhibitors, it can be not only used for outside animal body, In vivo study, it can also be used for human vitronectin system research, and since the inhibiting effect of hydrochloric acid Atipamezole is drug prototype it is not metabolite, preincubate need not be carried out when carrying out in vitro study as instrument medicine, it need not be administered in advance when In vivo study, there is the clear superiority for substituting existing 1 ABT of classical tool medicine.
Description
Technical field
The present invention relates to the new opplication of veterinary drug hydrochloric acid Atipamezole, specially hydrochloric acid Atipamezole is non-specific as the second generation
The application of property P450 enzyme inhibitors.
Background technology
The reset mode of drug in vivo includes mainly being metabolized and draining two kinds of approach, and wherein metabolic conversion relies primarily on medicine
Object is metabolized enzymatic.Drug metabolic enzyme includes I phases and II phase metabolic enzymes, and wherein I phases metabolic enzyme is main metabolic enzyme, and P450
Enzyme (CYP enzymes) is main I phases metabolic enzyme, and P450 enzymes are a superfamilies, wherein again same comprising multiple responsible drug metabolisms
Work enzyme.Whether drug is very crucial one of ADME properties through P450 enzyme metabolite clearances, determines that can it patent medicine and potential
Potential applicability in clinical practice.Therefore in drug discovery early stage, using nonspecific P450 enzyme inhibitors as tool drug
It can determine the metabolite clearance compound contribution in total body clearance in vivo that P450 enzymes mediate, can determine whether that compound is according to result
The no interaction that can occur based on P450 enzymes, whether be susceptible to crowd be metabolized variation and whether need further evaluate and
Exploitation.The prerequisite of non-specific P450 enzyme inhibitors as instrument medicine is their ability to non-specifically inhibit all
P450 isodynamic enzymes play the role of chemical method and knock out P450 genes.
1- amino benzotriazole (1-aminobenzotriazole, 1-ABT) is the non-specificity of classics based on mechanism
P450 enzyme inhibitors.By after P450 enzyme metabolic activations, product can covalently be tied 1-ABT itself with the prosthetic heme group of P450 enzymes
It closes, leads to the reduction of P450 enzymatic activity non-specificity.It is right largely studies have shown that 1-ABT can be applied in vitro and in vivo research
The P450 enzymes of people and common experimental animal (rat, rabbit, cavy etc.) all have non-specific inhibiting effect.Conventional is external
Experimental method is that 1-ABT the and NADPH preincubates 15- of high concentration (1mM) is first added in hepatomicrosome or liver cell system
After 30min, the probe substrate of each P450 isodynamic enzymes is added.A large amount of experiment in vitro prove, to CYP after 1-ABT (1mM) preincubate
Multiple isodynamic enzymes have obvious inhibiting effect in enzyme, especially to CYP2A6 and 3A4, can almost completely inhibit its work
With；But not etc. (19-58%) to the rejection ability power of other several isodynamic enzymes, in addition to the inhibition to CYP2C19 and CYP2E1
Effect be significantly stronger than other than its specific inhibitor, to other several isodynamic enzymes include CYP1A2, CYP2B6, CYP2C8,
The inhibiting effect of CYP2C9 and CYP2D6 is below respective specific inhibitor, especially very to the inhibiting effect of CYP2C9
It is weak, such as in rat liver microsomes system, 50 μM of 1-ABT is only capable of what 60% inhibition CYP2C was relied on
The 4- hydroxylatings of cyclophosphamide, the 1-ABT of 1mM is only capable of inhibiting 40% or so double chlorine in people's hepatomicrosome
Fragrant acid hydroxylating.Since the substrate of CYP2C9 mostly contains carboxylic acid group, and 1-ABT lacks carboxylic acid negative charge and explains portion
Divide reason, therefore 1-ABT is apparently higher than Diclofenac to the rejection ability of the CYP2C9 S- neodicoumarin hydroxylatings mediated.By
All it is the substrate of CYP2C9 in many clinical medicines, this defect of 1-ABT may obviously underestimate the effect of CYP2C9, to
Cause the deviation of result.There is the inhibiting effect intensity to each isodynamic enzyme as classical P450 enzyme non-specific inhibitors in 1-ABT
It obviously differs, problem especially weaker to the rejection ability of CYP2C9, usually needs careful consideration to test in practical application
It it is the early stage that drug metabolism Mechanism Study and compound metabolism remove property as a result, when necessary with other inhibitor use in conjunction
Evaluation brings great uncertainty.
To solve this critical issue, as can the stronger non-specificity P450 enzyme inhibitors replacement 1-ABT of discovery effect will
It is significantly.
Hydrochloric acid Atipamezole is a for having glyoxaline structure2Adrenoceptor antagonists can quickly and effectively restore
The anesthesia and calmness of animal mitigate adverse reaction caused by isoflurane or Patients Under Ketamine Anesthesia.Clinically commonly use hydrochloric acid Atipamezole
Calm or bradycardia caused by the animals such as antagonism Medetomidine anesthetized cat, dog, pig, while hydrochloric acid Atipamezole can effectively delay
Solve adverse reaction caused by Dexmedetomidine-midazolam-ketamine combined anesthesia.
Invention content
The problem to be solved in the present invention is found to the preferable P450 enzymes of each isodynamic enzyme inhibiting effect of P450 by screening
Non-specific inhibitors provide better instrument medicine as second generation instrument medicine, for drug screening and drug metabolism Mechanism Study.
The present invention has found in screening drug interaction potential, hydrochloric acid Atipamezole to each major isoenzyme of P450 enzymes all
It significantly inhibits, and inhibition strength is higher, it is with obvious effects better than classical similar tools medicine 1-ABT, it can conduct
P450 enzymes nonspecific inhibitor of new generation.
The present invention passes through in vitro in the liver microsomes incubation system of three kinds (rat, dog and people), studying hydrochloric acid
Atipamezole finds that hydrochloric acid Atipamezole is bright as P450 enzyme nonspecific inhibitors to the inhibiting effect of P450 major isoenzymes
It is aobvious to be better than classical similar tools medicine 1-ABT, it shows：
1, hydrochloric acid Atipamezole is non-specific good to the inhibiting effect no significant difference of each major isoenzyme of P450 enzymes；Institute
It includes CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 to state P450 isodynamic enzymes；
2, hydrochloric acid Atipamezole can carry out kind extrapolation to the inhibiting effect of P450 enzymes without apparent species variation；
3, IC of the hydrochloric acid Atipamezole to P450 enzyme inhibitions50Value is significantly lower than 1-ABT, and rejection ability is strong, using agent
It is small to measure (concentration)；
4, the physicochemical property of hydrochloric acid Atipamezole is good, solubility is good, and stability is good, no obvious toxic-side effects, external internal
Using safe and reliable；
5, hydrochloric acid Atipamezole is non-time dependent to the inhibiting effect of metabolic enzyme, during preincubate be added and not
After NADPH startup reactions are added, hydrochloric acid Atipamezole does not substantially change the inhibiting effect of each CYP isodynamic enzymes, prompts main
It is that drug prototype hydrochloric acid Atipamezole plays inhibiting effect.Preincubate need not be carried out when in vitro study, greatly simplify experimental implementation
Flow.
The present invention can be not only used for animal body using veterinary drug hydrochloric acid Atipamezole as a new generation's P450 enzyme nonspecific inhibitors
Outside, In vivo study, it can also be used to which human vitronectin system research, inhibiting effect are substantially better than existing classical tool medicine 1-ABT.
Medical compounds is removed in vitro using hydrochloric acid Atipamezole screening study P450 enzymes the present invention also provides a kind of
Medical compounds and hydrochloric acid Atipamezole to be measured is added in the method for effect in liver microsomes incubation system, be not added with hydrochloric acid Ah
For U.S. azoles as negative control, the external clearance rate (CL of medical compounds more to be measuredint) ratio, according to formula contribution degree
(fm)=[1-CLInt+ Atipamezoles/CLInt- Atipamezoles] × 100% judges the contribution that P450 enzymes remove medical compounds In vitro metabolism.
Wherein, concentration of the hydrochloric acid Atipamezole in liver microsomes incubation system is preferably 10~50 μM, more preferably 20~30 μM.
A method of using hydrochloric acid Atipamezole screening study P450 enzymes to scavenging effect in medical compounds body, simultaneously
Medical compounds to be measured and hydrochloric acid Atipamezole are taken orally, not take hydrochloric acid Atipamezole as negative control, medicine more to be measured
Drug prototype exposed amount (AUC) changes ratio in compounds body, according to formula contribution degree (fm)=[1-AUCAtipamezole/
AUC+ Atipamezole] × 100% judges contribution of the P450 enzymes to metabolite clearance in medical compounds body.Wherein, hydrochloric acid Atipamezole is given
The oral dose of rat is preferably 2~4mg/kg, more preferably 3mg/kg.
In above-mentioned technical proposal, hydrochloric acid Atipamezole is determined as the tool drug of nonspecific P450 enzyme inhibitors
Contribution of the metabolite clearance that P450 enzymes mediate in medical compounds total body clearance, provides for drug screening and drug metabolism mechanism
Method and foundation.
Description of the drawings
Fig. 1 is hydrochloric acid Atipamezole to the time dependent inhibiting effect of CYP1A2；
Fig. 2 is hydrochloric acid Atipamezole to the time dependent inhibiting effect of CYP2B6；
Fig. 3 is hydrochloric acid Atipamezole to the time dependent inhibiting effect of CYP2C8；
Fig. 4 is hydrochloric acid Atipamezole to the time dependent inhibiting effect of CYP2C9；
Fig. 5 is hydrochloric acid Atipamezole to the time dependent inhibiting effect of CYP2C19；
Fig. 6 is hydrochloric acid Atipamezole to the time dependent inhibiting effect of CYP2D6；
Fig. 7 is hydrochloric acid Atipamezole to the time dependent inhibiting effect of CYP3A4.
Specific implementation mode
The present invention is by vitro in the liver microsomes incubation system of three kinds (rat, dog and people), using P450
Isodynamic enzyme probe substrate method research hydrochloric acid Atipamezole finds hydrochloric acid Atipamezole pair to the inhibiting effect of P450 major isoenzymes
The substrate utilization reaction that three kind P450 major isoenzymes mediate has apparent inhibiting effect.The results show that hydrochloric acid Ah replacing
U.S. azoles, which is metabolized the probe substrate that CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, CYP2D6 and CYP3A4 are mediated, to be made
With there is inhibiting effect, 1-ABT especially is significantly stronger than to the inhibiting effect of CYP2C9, and without apparent species variation.
The external drug interaction scale-model investigation that application time of the present invention relies on also found that hydrochloric acid Atipamezole is to metabolism
The inhibiting effect of enzyme is non-time dependent, after being added and being added without NADPH startup reactions during preincubate, hydrochloric acid Ah replacing
U.S. azoles does not substantially change the inhibiting effect of each CYP isodynamic enzymes, prompts to be mainly that drug prototype hydrochloric acid Atipamezole plays suppression
It makes and uses.
Since hydrochloric acid Atipamezole does not have significant difference to the rejection ability of each isodynamic enzyme, especially to the inhibition of CYP2C9
Effect is significantly stronger than 1-ABT, and species variation is small, can be not only used for outside animal body, In vivo study, it can also be used to which human vitronectin system is ground
Study carefully；And since the inhibiting effect of hydrochloric acid Atipamezole is drug prototype be not metabolite, it need not when carrying out in vitro study
Preincubate is carried out, when In vivo study need not be administered in advance, have the clear superiority for substituting existing classical tool medicine 1-ABT.Cause
This, hydrochloric acid Atipamezole can be used as a new generation's P450 enzyme nonspecific inhibitors.
Tool drug of the hydrochloric acid Atipamezole as nonspecific P450 enzyme inhibitors can be used in measuring P450 enzymes Jie
Contribution of the metabolite clearance led in medical compounds total body clearance, be drug screening and drug metabolism mechanism providing method and according to
According to.
The present invention is using hydrochloric acid Atipamezole screening study P450 enzymes to the method packet of the external scavenging effect of medical compounds
It includes, medical compounds and hydrochloric acid Atipamezole to be measured is added in liver microsomes incubation system, to be not added with hydrochloric acid Atipamezole work
For negative control.External clearance rate (the CL of medical compounds more to be measuredint) ratio, according to formula contribution degree (fm)=[1-
CLInt+ Atipamezoles/CLInt- Atipamezoles] × 100% judges the contribution that P450 enzymes remove medical compounds In vitro metabolism.In the present invention,
The type of small molecule drug compound to be measured is not particularly limited, any kind of compound could be used for small point of the present invention
In sub- medical compounds screening.
Wherein, in liver microsomes incubation system, albumen concentration is preferably 0.1~1mg/ml, more preferably 0.5mg/ml；It waits for
It is preferably 1~2 μM to survey concentration of the medical compounds in liver microsomes incubation system；Hydrochloric acid Atipamezole is in liver microsomes incubation
Concentration in system is preferably 10~50 μM, more preferably 20~30 μM.The present invention, which is preferably started with NADPH, to react, described
The concentration of NADPH is preferably 1~2mM.Ice acetonitrile is added preferably in the incubation system and terminates reaction by the present invention.The present invention is incubated
The temperature for educating reaction is preferably 36~38 DEG C, more preferably 37 DEG C；The time of the incubation reaction is preferably 10~60min, more
Preferably 20~40min.When reaction terminating, the external clearance rate of medical compounds is measured.
External clearance rate computational methods of the present invention are preferably：
Concentration when the zero of each medical compounds to be measured is set as 100%, the medical compounds concentration of different incubation time points
Remaining percentage of the medical compounds at each time point is obtained compared with concentration when zero, by each time point residue of medical compounds hundred
The natural logrithm and the linear recurrence of incubation time for dividing ratio obtain slope (- k), and hydrochloric acid Atipamezole is obtained micro- by formula (1)
The T being metabolized in plastochondria1/2(min)；
T1/2=-0.693/k (1)
Extrapolation is carried out to hepatomicrosome data by Well StierredModel and obtains medical compounds in different genera liver
Intrinsic clearance CL in microsomeint(mL·min-1·kg-1) (formula 2)
Wherein, in formula (2), X is the common scale factor of different genera (g liver weight/kg weight), such as people=20；Beasle dog
=25；Rat=45.
The ratio variation of medical compounds to be evaluated In vitro metabolism clearance rate after adduction is not added with hydrochloric acid Atipamezole is calculated,
According to formula contribution degree (fm)=[1-CLInt+ Atipamezoles/CLInt- Atipamezoles] × 100% judges P450 enzymes to medical compounds external generation
Thank to the contribution of removing.
In the present invention, the probe substrate of each isodynamic enzymes of P450 is added in liver microsomes incubation system, be added hydrochloric acid Ah
Start reaction to be not added with hydrochloric acid Atipamezole as negative control as positive control for U.S. azoles with NADPH and be incubated, incubated
After educating, each probe substrate external intrinsic clearance (CL after adduction is not added with hydrochloric acid Atipamezole is calculatedint) ratio, e.g.,
CLInt+ Atipamezoles/CLInt- Atipamezoles<0.2, then prove that hydrochloric acid Atipamezole inhibits P450 enzymatic activitys substantially, the system is reliable.
The present invention is using hydrochloric acid Atipamezole screening study P450 enzymes to the method for scavenging effect in medical compounds body, packet
It includes：Medical compounds to be measured is taken orally simultaneously with hydrochloric acid Atipamezole to compare not take hydrochloric acid Atipamezole as negative control
Drug exposure changes ratio in medical compounds body to be measured, judges tribute of the P450 enzymes to metabolite clearance in medical compounds body
It offers.
The present invention preferably applies pharmacokinetic methods to measure in the medical compounds body to be measured in different time sections
Drug exposure (AUC).According to formula contribution degree (fm)=[1-AUCAtipamezole/AUC+ Atipamezole] × 100% judges P450 enzymes to medicine
The contribution of metabolite clearance in compounds body.
In the present invention, oral object can be such as rat or dog animal, or people.The present invention is according to drug to be measured
The oral dose that the oral recommended dose setting of compound adapts to.Oral dose of the hydrochloric acid Atipamezole of the present invention to rat
Preferably 2~4mg/kg, more preferably 3mg/kg.
To make the objectives, technical solutions, and advantages of the present invention clearer, with reference to embodiment to the present invention into
Row detailed description, but they cannot be interpreted as limiting the scope of the present invention.
Embodiment 1
Inhibiting effect of the hydrochloric acid Atipamezole to each isodynamic enzymes of CYP
Each same works of CYP shown in table 1 are added in rat, dog and people's hepatomicrosome solution (albumen concentration 0.5mg/ml) respectively
The hydrochloric acid of the probe substrate of enzyme and 0~100 μM of series concentration (0,0.091,0.412,1.23,3.7,11.1,33.3,100 μM)
After Atipamezole preincubate 5min, NADPH (final concentration of 1mM) is added and starts reaction, 37 DEG C of common incubations, incubation time is shown in Table
1.After the completion of incubation, ice acetonitrile is added and terminates and reacts, high speed centrifugation after vortex takes supernatant LC-MS/MS to measure each probe substrate
The production quantity of metabolite.Logarithm will be converted into various concentration hydrochloric acid Atipamezole, under each concentration metabolite production quantity with
Blank control group is fitted, and then obtain hydrochloric acid Atipamezole to each kind P450 compared to ratio is obtained using Prism softwares
Half-inhibition concentration (the IC of major isoenzyme50)。
Concentration and incubation time of the probe substrate of 1 each hypotype of CYP enzymes of table in liver microsomes incubation liquid
Comparative example 1
Inhibiting effect of the 1-ABT to each isodynamic enzymes of CYP
It is each same that CYP shown in table 1 in embodiment 1 is added in rat liver microsomes liquid solution (albumen concentration 0.5mg/ml) respectively
The 1-ABT of the probe substrate and 0~10mM series concentrations (0,0.91,4.12,12.3,71.111,333,1000 μM) of work enzyme is pre-
After being incubated 5min, NADPH (final concentration of 1mM) is added and starts reaction, 37 DEG C are incubated jointly, and incubation time is shown in Table 1.It is incubated and completes
Afterwards, ice acetonitrile is added and terminates and react, high speed centrifugation after vortex takes supernatant to measure each probe substrate metabolite with LC-MS/MS
Production quantity.It will be converted into logarithm in various concentration 1-ABT, the ratio that metabolite production quantity and blank control group are compared under each concentration
Value, is fitted, and then obtain half-inhibition concentrations of the 1-ABT to each kind P450 major isoenzymes using Prism softwares
(IC50)。
The inhibiting effect of 2 hydrochloric acid Atipamezole of table and 1-ABT to each kind P450 major isoenzymes
As can be seen from Table 2, the substrate utilization reaction that three kind P450 major isoenzymes of hydrochloric acid Atipamezole pair mediate
There are apparent inhibiting effect, IC50Value is significantly lower than 1-ABT；1-ABT especially is significantly stronger than to the inhibiting effect of CYP2C9,
And without apparent species variation.
Embodiment 2
Hydrochloric acid Atipamezole is based on time dependent inhibiting effect to CYP enzymes
Incubation is divided into two groups, and one group starts reaction group for NADPH is added, and another group does not start reaction to be added without NADPH
Group.
Be added in rat liver microsomes liquid solution (albumen concentration 0.5mg/ml) and 0~100 μM of series concentration (0,0.091,
0.412,1.23,3.7,11.1,33.3,100 μM) hydrochloric acid Atipamezole, be added or be added without NADPH (final concentration of 1mM)
It is incubated 30min, each isodynamic enzyme probe substrate is added according to concentration shown in table 1 later, is incubated jointly at 37 DEG C, removes CYP2C19
The appropriate incubation times of probe substrate (S)-Mei Fen be outside 30min, the incubation time of remaining probe substrate is 10min.It has been incubated
It terminates and reacts at rear addition ice acetonitrile, high speed centrifugation after vortex takes supernatant LC-MS/MS to measure each probe substrate metabolite
Production quantity will be converted into logarithm, metabolite production quantity and blank control group under each concentration in various concentration hydrochloric acid Atipamezole
The ratio compared is fitted using Prism softwares, and then obtains hydrochloric acid Atipamezole to each kind P450 major isoenzymes
Half-inhibition concentration (IC50)。
Fig. 1~7 are hydrochloric acid Atipamezole to the time dependent inhibiting effect of CYP major isoenzymes.It can be seen by Fig. 1~7
Go out, after being added and being added without NADPH startup reactions during preincubate, inhibition of the hydrochloric acid Atipamezole to each CYP isodynamic enzymes
Curve essentially coincides, and the addition of NADPH inhibits the effect of CYP enzymes not substantially change hydrochloric acid Atipamezole, illustrate hydrochloric acid Ah
It is non-time dependent to the inhibiting effect of metabolic enzyme for U.S. azoles, prompts to be mainly that drug prototype hydrochloric acid Atipamezole plays inhibition
Effect.
Embodiment 3
Be added in the hepatomicrosome solution (albumen concentration 0.5mg/ml) of rat 1 μM of ZC56 medical compounds to be evaluated,
20 μM of hydrochloric acid Atipamezole, and to be added without hydrochloric acid Atipamezole as negative control, after 37 DEG C of preincubate 5min, be added
NADPH 1mM start reaction, and ice acetonitrile, which is added, respectively at 5,15,30,60min terminates reaction.Medical compounds is calculated in rat
Intrinsic clearance CL in hepatomicrosomeint, computational methods are as follows：
Concentration when the zero of medical compounds to be measured is set as 100%, different incubation time point concentration are when zero compared with concentration
The remaining percentage of medical compounds is obtained, by the natural logrithm and incubation time of each time point residue percentage of medical compounds
Linear recurrence obtains slope (- k), and the T that Atipamezole is metabolized in microsome is obtained by formula (1)1/2(min), then by Well
StierredModel carries out extrapolation to hepatomicrosome data and obtains intrinsic clearance CL of the drug in rat liver microsomesint
(mL·min-1·kg-1) (formula 2)
T1/2=-0.693/k (1)
Wherein, it is 45 than putting factor X in rat liver microsomes, a concentration of 0.5mg/ml of hepatomicrosome albumen, hepatomicrosome
Mg/ liver weights g is empirical value 45；ZC56 is not added with the naturally right of external each time point residue percentage after hydrochloric acid Atipamezole in adduction
It is respectively 0.0042 and 0.0236, T that number obtains slope (- k) with the linear recurrence of incubation time1/2Respectively 165min and
26.5min.ZC56 In vitro metabolisms after adduction is not added with hydrochloric acid Atipamezole are calculated according to formula 2 remove difference according to experimental result
For 17.0 and 106.7mLmin-1·kg-1, according to formula contribution degree (fm)=[1-CLInt+ Atipamezoles/CLInt- Atipamezoles] × 100%
Judge that P450 enzymes participate in the compound metabolism and remove contribution as 84%.
Embodiment 4
The positive control research of research system reliability is carried out at the same time when evaluating and screening compound
Be added in the hepatomicrosome solution (albumen concentration 0.5mg/ml) of rat 1 μM of mixed probe substrate (phenacetin,
Diclofenac, (S)-Mephenetoin, dextromethorphan, midazolam) and 20 μM of hydrochloric acid Atipamezole, and to be added without hydrochloric acid Ah replacing
U.S. azoles is as negative control, after 37 DEG C of preincubate 5min, NADPH 1mM is added and start reaction, add respectively at 5,15,30,60min
Enter ice acetonitrile and terminates reaction.Calculate intrinsic clearance CL of the mixed probe substrate in rat liver microsomesint, according to formula tribute
Degree of offering (fm)=[1-CLInt+ Atipamezoles/CLInt- Atipamezoles] × 100% calculates P450 enzymes to the contribution degree of each probe substrate, as a result shows
Show that hydrochloric acid Atipamezole can obviously inhibit each probe substrate in the In vitro metabolism of rat liver microsomes, contribution degree fmIt is all higher than 80%
(table 3), it is believed that the system is reliable.
3 mixed probe substrate of table is not added with after hydrochloric acid Atipamezole as positive control adduction and is metabolized in rat liver microsomes
Stability
Embodiment 5
Rat 10, is randomly divided into two groups, every group 5, wherein first group of gavage medical compounds ZC56 to be measured simultaneously
(2mg/kg) and hydrochloric acid Atipamezole (3mg/kg), second group of only gavage ZC56 (2mg/kg).Different time points (5,15,30,
60min, 2,4,6,8,12h) blood sampling, separated plasma, using LC-MS/MS measurement plasma drug levels, according to different time points medicine
Object concentration calculates separately the plasma exposure amount (AUC) of ZC56 in two groups.
After gavage 12h, the plasma exposure amount (AUC) of ZC56 is respectively 158396 ± 99512 Hes in first group and second group
469937 ± 175113ng/ml*min, according to formula contribution degree (fm)=[1-AUC-Atipamezole/AUC+ Atipamezole] × 100% judges
P450 enzymes are 67% to the contribution of metabolite clearance in medical compounds body.
The above is only a preferred embodiment of the present invention, it is noted that for the ordinary skill people of the art
For member, various improvements and modifications may be made without departing from the principle of the present invention, these improvements and modifications are also answered
It is considered as protection scope of the present invention.
Claims (6)
1. application of the hydrochloric acid Atipamezole as non-specificity P450 enzyme inhibitors.
2. application according to claim 1, which is characterized in that the P450 enzymes include CYP1A2, CYP2B6, CYP2C8,
CYP2C9, CYP2C19, CYP2D6 and CYP3A4.
3. it is a kind of using hydrochloric acid Atipamezole screening study P450 enzymes to the method for the external scavenging effect of medical compounds, feature
It is, medical compounds and hydrochloric acid Atipamezole to be measured is added in liver microsomes incubation system, is not added with hydrochloric acid Atipamezole
As negative control, the external clearance rate CL of medical compounds more to be measuredintRatio, according to formula contribution degree (fm)=[1-
CLInt+ Atipamezoles/CLInt- Atipamezoles] × 100% judges the contribution that P450 enzymes remove medical compounds In vitro metabolism.
4. according to the method described in claim 3, it is characterized in that, the hydrochloric acid Atipamezole is in liver microsomes incubation system
A concentration of 10~50 μM.
5. a kind of studying method of the P450 enzymes to scavenging effect in medical compounds body using hydrochloric acid Atipamezole, feature exists
In, while taking orally medical compounds to be measured and comparing not take hydrochloric acid Atipamezole as negative control with hydrochloric acid Atipamezole
The variation ratio of drug exposure AUC in medical compounds body to be measured judges P450 enzymes to metabolite clearance in medical compounds body
Contribution, contribution degree calculates according to following formula：
Contribution degree (fm)=[1-AUCAtipamezole/AUC+ Atipamezole] × 100%.
6. according to the method described in claim 5, it is characterized in that, when using rat as internal pharmacokinetic model,
The hydrochloric acid Atipamezole is 2~4mg/kg to the oral dose of rat.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810253970.0A CN108403692B (en) | 2018-03-26 | 2018-03-26 | Application of the hydrochloric acid Atipamezole as non-specificity P450 enzyme inhibitor |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201810253970.0A CN108403692B (en) | 2018-03-26 | 2018-03-26 | Application of the hydrochloric acid Atipamezole as non-specificity P450 enzyme inhibitor |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN108403692A true CN108403692A (en) | 2018-08-17 |
| CN108403692B CN108403692B (en) | 2019-08-16 |
Family
ID=63132493
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201810253970.0A Active CN108403692B (en) | 2018-03-26 | 2018-03-26 | Application of the hydrochloric acid Atipamezole as non-specificity P450 enzyme inhibitor |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN108403692B (en) |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101889003A (en) * | 2007-12-05 | 2010-11-17 | 格林代克斯联合股份公司 | Process for the preparation of 5-(2-ethyl-dihydro-1h-inden-2-yl)-1h-imidazole and salts thereof |
| US20140107135A1 (en) * | 2009-07-28 | 2014-04-17 | Auspex Pharmaceuticals, Inc. | Pyrimidinone inhibitors of lipoprotein-associated phospholipase a2 |
| CN104274415A (en) * | 2013-07-04 | 2015-01-14 | 青岛康地恩动物药业有限公司 | Atipamezole hydrochloride-containing calming and pain easing tablet for pets, and preparation method thereof |
-
2018
- 2018-03-26 CN CN201810253970.0A patent/CN108403692B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN101889003A (en) * | 2007-12-05 | 2010-11-17 | 格林代克斯联合股份公司 | Process for the preparation of 5-(2-ethyl-dihydro-1h-inden-2-yl)-1h-imidazole and salts thereof |
| US20140107135A1 (en) * | 2009-07-28 | 2014-04-17 | Auspex Pharmaceuticals, Inc. | Pyrimidinone inhibitors of lipoprotein-associated phospholipase a2 |
| CN104274415A (en) * | 2013-07-04 | 2015-01-14 | 青岛康地恩动物药业有限公司 | Atipamezole hydrochloride-containing calming and pain easing tablet for pets, and preparation method thereof |
Non-Patent Citations (2)
| Title |
|---|
| 于敏: "细胞色素P450酶系体外药物代谢研究方法进展", 《中国药事》 * |
| 尹柏双: "阿替美唑药理特性及其在动物麻醉中的应用", 《黑龙江畜牧兽医》 * |
Also Published As
| Publication number | Publication date |
|---|---|
| CN108403692B (en) | 2019-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Weiss | Metabolomics and metabolic reprogramming in kidney cancer | |
| McCoubrey et al. | Predicting drug-microbiome interactions with machine learning | |
| Mougey et al. | Absorption of montelukast is transporter mediated: a common variant of OATP2B1 is associated with reduced plasma concentrations and poor response | |
| Fries et al. | Marked interindividual variability in the response to selective inhibitors of cyclooxygenase-2 | |
| Synnestvedt et al. | Ecto-5′-nucleotidase (CD73) regulation by hypoxia-inducible factor-1 mediates permeability changes in intestinal epithelia | |
| Lönnqvist et al. | A pathogenic role of visceral fat beta 3-adrenoceptors in obesity. | |
| Schwarzschild et al. | Serum urate as a predictor of clinical and radiographic progression in Parkinson disease | |
| Park et al. | Discovery and biological evaluation of novel α-glucosidase inhibitors with in vivo antidiabetic effect | |
| Wang et al. | Research progress of MEK1/2 inhibitors and degraders in the treatment of cancer | |
| El-Sherbeni et al. | Repurposing resveratrol and fluconazole to modulate human cytochrome P450-mediated arachidonic acid metabolism | |
| JP6934481B2 (en) | Identification of patient response to S1P receptor modulator administration | |
| Aliaga et al. | Preservation of contractile reserve and diastolic function by inhibiting the NLRP3 inflammasome with OLT1177®(dapansutrile) in a mouse model of severe ischemic cardiomyopathy due to non-reperfused anterior wall myocardial infarction | |
| Krimm et al. | Binding evaluation of fragment-based scaffolds for probing allosteric enzymes | |
| Chitneni et al. | Synthesis and evaluation of a 18F-Labeled triazinediamine analogue for imaging mutant idh1 expression in gliomas by PET | |
| Yco et al. | Effect of sulfasalazine on human neuroblastoma: analysis of sepiapterin reductase (SPR) as a new therapeutic target | |
| JP2008538102A (en) | Screening method of protein kinase B inhibitor using virtual docking approach, and compound and composition found thereby | |
| Machado et al. | The p38 MAPK inhibitors and their role in inflammatory diseases | |
| Maheshwari et al. | Design, synthesis and biological evaluation of some tetrazole acetamide derivatives as novel non-carboxylic PTP1B inhibitors | |
| Wang et al. | Diversity and similarity of motor function and cross-bridge kinetics in papillary muscles of transgenic mice carrying myosin regulatory light chain mutations D166V and R58Q | |
| Olher et al. | Isometric exercise improves redox balance and blood pressure in hypertensive adults | |
| Lever et al. | Characterization of pulmonary sigma receptors by radioligand binding | |
| Khosravi et al. | The role of PPAR-γ and NFKB genes expression in muscle to improve hyperglycemia in STZ-induced diabetic rat following magnesium sulfate administration | |
| Reineke et al. | SRC-2 coactivator deficiency decreases functional reserve in response to pressure overload of mouse heart | |
| Gladwin et al. | Update on pulmonary hypertension 2009 | |
| CN108403692B (en) | Application of the hydrochloric acid Atipamezole as non-specificity P450 enzyme inhibitor |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant |